THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 101 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $0 | – | 0 | – | 0.00% | – |
| Q4 2023 | $0 | – | 0 | – | 0.00% | – |
| Q3 2023 | $0 | – | 0 | – | 0.00% | – |
| Q2 2023 | $0 | – | 0 | – | 0.00% | – |
| Q1 2023 | $0 | – | 0 | – | 0.00% | – |
| Q4 2022 | $0 | – | 0 | – | 0.00% | – |
| Q3 2022 | $0 | – | 0 | – | 0.00% | – |
| Q2 2022 | $0 | – | 0 | – | 0.00% | – |
| Q1 2022 | $0 | – | 0 | – | 0.00% | – |
| Q4 2021 | $0 | – | 0 | – | 0.00% | – |
| Q3 2021 | $0 | – | 0 | – | 0.00% | – |
| Q2 2021 | $0 | – | 0 | – | 0.00% | – |
| Q1 2021 | $0 | – | 0 | – | 0.00% | – |
| Q4 2020 | $0 | – | 0 | – | 0.00% | – |
| Q3 2020 | $0 | – | 0 | – | 0.00% | – |
| Q2 2020 | $0 | – | 0 | – | 0.00% | – |
| Q3 2018 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q2 2018 | $14,040,000 | -9.6% | 619,085 | -3.3% | 0.08% | -8.0% |
| Q1 2018 | $15,528,000 | -61.7% | 640,355 | -56.0% | 0.09% | -60.4% |
| Q4 2017 | $40,556,000 | -26.6% | 1,454,167 | -9.9% | 0.22% | -29.7% |
| Q3 2017 | $55,234,000 | -21.0% | 1,613,167 | -8.1% | 0.32% | -22.5% |
| Q2 2017 | $69,903,000 | +3.4% | 1,754,600 | -4.4% | 0.41% | +1.5% |
| Q1 2017 | $67,600,000 | +15.2% | 1,835,984 | -0.3% | 0.40% | +12.6% |
| Q4 2016 | $58,705,000 | +55.2% | 1,841,455 | +76.4% | 0.36% | +54.5% |
| Q3 2016 | $37,824,000 | +63.2% | 1,043,733 | +2.2% | 0.23% | +62.7% |
| Q2 2016 | $23,171,000 | +21.4% | 1,021,233 | +0.6% | 0.14% | +21.4% |
| Q1 2016 | $19,092,000 | +10.2% | 1,015,541 | -3.9% | 0.12% | +10.4% |
| Q4 2015 | $17,329,000 | +35.9% | 1,057,292 | -8.9% | 0.11% | +29.3% |
| Q3 2015 | $12,751,000 | -16.5% | 1,160,295 | -1.0% | 0.08% | -8.9% |
| Q2 2015 | $15,267,000 | -32.3% | 1,172,589 | -9.7% | 0.09% | -30.8% |
| Q1 2015 | $22,536,000 | +4.4% | 1,298,947 | -10.2% | 0.13% | +6.6% |
| Q4 2014 | $21,588,000 | -23.4% | 1,446,960 | +18.3% | 0.12% | -25.6% |
| Q3 2014 | $28,182,000 | +194.0% | 1,222,665 | +306.6% | 0.16% | +168.9% |
| Q2 2014 | $9,587,000 | – | 300,732 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
| Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
| Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
| Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
| Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
| Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
| Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
| Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |